Chronic Myeloproliferative Disorders Completed Phase 3 Trials for Ketamine (DB01221)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00516503Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With CancerSupportive Care